Cancel

Novel Breast Cancer Therapies: Antibody-Drug Conjugates

STATEMENT OF NEED Breast cancer is the most common cancer diagnosed in women, with an estimated 15% of cases being human epidermal growth factor receptor 2 (HER2)"positive and 12% being triple-negative (ACS, 2019). Antibody-drug conjugates have revolutionized the treatment of HER2-positive, triple-negative, and, most recently, HER2-low unresectable or metastatic breast cancer. These drugs combine a tumor antigen"targeted monoclonal antibody with a cytotoxic payload to permit the s...
i3 Health

Novel Breast Cancer Therapies: Immune Checkpoint Inhibitors

STATEMENT OF NEED Breast cancer is the most common cancer diagnosed in women, and it is estimated that 12% of cases are classified as triple-negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) (ACS, 2019). Immune checkpoint inhibition in combination with chemotherapy is a new strategy in breast cancer, with the first immunotherapy approval for patients with advanced triple-negative disease occurring in 2019. Immune checkpoint inhibit...
i3 Health

Novel Breast Cancer Therapies: CDK4/6 Inhibitors

STATEMENT OF NEED Breast cancer is the most common cancer diagnosed in women, with 287,850 new cases and 43,250 deaths predicted to occur in 2022 (ACS, 2022). Making up 73% of cases, hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative disease is the most common subtype of breast cancer (ACS, 2019). Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are a novel therapeutic option for patients with HR-positive, HER2-negative advanced breast cancer. T...
i3 Health

Novel Breast Cancer Therapies: HER2 Tyrosine Kinase Inhibitors

STATEMENT OF NEED Breast cancer is the most common cancer diagnosed in women, and it is estimated that 15% of cases are HER2-positive and may therefore benefit from human epidermal growth factor receptor 2 (HER2) inhibition (ACS, 2019). By blocking downstream oncogenic signaling in HER2-positive breast cancer cells, HER2 tyrosine kinase inhibitors improve outcomes for patients with HER2-positive breast cancer. These agents have advantages over monoclonal antibody HER2 inhibitors because the...
i3 Health

Novel Breast Cancer Therapies: Monoclonal Antibodies

STATEMENT OF NEED Breast cancer is the most common cancer diagnosed in women, and it is estimated that 15% of cases are human epidermal growth factor receptor 2 (HER2)"positive and may therefore benefit from HER2 inhibition (ACS, 2019). Monoclonal antibodies target HER2 function by preventing the formation or blocking the signaling of the oncogene HER2. The resulting loss of signaling downregulates oncogenic signaling in the cancer cell, resulting in improved clinical outcomes for pati...
i3 Health

Novel Breast Cancer Therapies: PARP Inhibitors

STATEMENT OF NEED Breast cancer is the most commonly diagnosed cancer in women. A BRCA1 or BRCA2 mutation is found in approximately 5% of patients with breast cancer and is detected in 30% of patients who have a family history of breast or ovarian cancer (ACS, 2019). In patients with human epidermal growth factor receptor 2 (HER2)"negative breast cancer with deleterious or suspected deleterious germline BRCA mutations, inhibition of poly"(ADP-ribose) polymerase (PARP) is highly ef...
i3 Health

Novel Breast Cancer Therapies: PI3K Inhibitors

STATEMENT OF NEED Breast cancer is the most diagnosed cancer in women, with hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative breast cancer being the most common subtype, making up 73% of cases (ACS, 2019). In breast cancer, phosphatidylinositol-3-kinase (PI3K) overactivation is often associated with an activating mutation in the catalytic alpha subunit of PI3K (PIK3CA). These activating mutations occur in more than one third of breast cancers...
i3 Health

Evolving Treatment Concepts and New Data in Advanced Prostate Cancer

STATEMENT OF NEED Prostate cancer is the most common tumor type affecting men in the United States. It is estimated that 268,490 new cases were diagnosed and that 34,500 people died of prostate cancer in 2022 (Siegel et al, 2022). Prostate cancer alone accounts for 27% of all cancer diagnoses in men (ACS, 2022). To optimize outcomes for patients with prostate cancer, it is critical for health care providers to be familiar with the most recent evidence on therapy selection, biomarker testing...
i3 Health

Cracking the Code for Improved Patient Outcomes in Advanced Renal Cell Carcinoma

STATEMENT OF NEED Renal cell carcinoma (RCC) comprises 2.4% of malignancies in adults worldwide (Makino et al, 2022). It is estimated that 79,000 new cases of kidney cancer were diagnosed in the US in 2022 (Siegel et al, 2022). RCC is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Several new therapies have been approved for RCC in recent years; therefore, it is important for the cancer care team to update their...
i3 Health

Oncology Data Advisor™: Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma

STATEMENT OF NEED Multiple myeloma is a clonal plasma cell malignancy characterized by several cytogenetic alterations. Treatment planning for individual patients is complicated by factors such as age, frailty, comorbidities, eligibility for autologous stem cell transplantation, and risk stratification (Kumar et al, 2022). Clinicians need to continually update their working knowledge of emerging data and consensus recommendations that can rationally inform clinical decision making. In Modul...
i3 Health

Virtual Tumor Board: Building Comprehensive Care Plans in Esophagogastric Cancers

STATEMENT OF NEED Esophagogastric cancers include tumors of the esophagus, esophageal junction, and stomach. Esophageal cancers are the twentieth most commonly diagnosed cancer in the United States, but the eleventh leading cause of cancer death, with an estimated 21,560 cases diagnosed annually and 16,120 deaths estimated in 2023 (NCCN, 2023; Siegel et al, 2023). Given the poor prognosis of esophagogastric cancers and the complexity of personalized care planning, interdisciplinary teamwork...
i3 Health

Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma

STATEMENT OF NEED Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bis...
i3 Health

Hitting the Target in HER2-Positive Metastatic Colorectal Cancer

STATEMENT OF NEED An estimated 153,020 new cases of colorectal cancer (CRC) are diagnosed annually, and 52,550 people die of the disease (Siegel et al, 2023). Approximately 22% of patients present with metastatic disease, which is associated with a dismal 5-year survival rate of 15% (SEER, 2022). Targeting biomarkers is a key strategy for expanding therapeutic options and improving outcomes in metastatic CRC. Human epidermal growth factor receptor 2 (HER2) amplification status and treatment...
i3 Health

Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma

STATEMENT OF NEED An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, inclu...
i3 Health

Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC

In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non"small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now! STATEMENT OF NEED Lung cancer is the second most commonly diagnosed cancer and the leading cause of death for men and women worldwide. In the Unite...
i3 Health

Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs

STATEMENT OF NEED Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack ...
i3 Health

Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma

STATEMENT OF NEED Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for these patients, treatment options are limited and prognosis is very poor. In recent decades, the ident...
i3 Health

Putting the Freeze on Cold Agglutinin Disease

STATEMENT OF NEED Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia (AIHA) in which antibodies cause hemolysis at cold temperatures, generally between 37º to 39º Fahrenheit. Approximately 1 in a million people are affected by CAD annually, with onset usually occurring between the ages of 40 and 80 years. Individuals commonly experience fatigue, dizziness, palpitations, and shortness of breath caused by the anemia; jaundice caused by degradation of hemoglobin i...
i3 Health

Managing Immune Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes: The Nurse’s View

STATEMENT OF NEED Immune checkpoint inhibitors, which alter immune regulatory pathways and promote cell-mediated destruction of tumor cells, have revolutionized the treatment of cancer in recent years, with numerous therapeutic agents approved and several targets under investigation (Chennamadhavuni et al, 2022). However, up to 90% of patients receiving immune checkpoint inhibitors experience immune-related adverse events, which can affect a wide variety of organ systems and can occur at any ...
i3 Health

Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults

STATEMENT OF NEED Acid sphingomyelinase deficiency (ASMD) is a rare, hereditary lysosomal storage disease with multisystemic manifestations, including splenomegaly, hepatomegaly, interstitial lung disease, dyslipidemia, bone marrow and lymph node involvement, and sometimes neurological and peripheral nerve involvement. While the most severe form of ASMD, infantile neurovisceral ASMD, results in death in early childhood, chronic forms of ASMD have more prolonged survival but are associated w...
i3 Health

Current Standards and New Directions in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

STATEMENT OF NEED Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy with a rapid onset and progression and a mortality rate of 10% to 20% with prompt treatment. Onset of aTTP is characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, and a constellation of associated symptoms including hemorrhage, neurologic and renal manifestations, cardiac abnormalities, and mesenteric ischemia (Joly et al, 2017). Survivors of f...
i3 Health

Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes

STATEMENT OF NEED Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ...
i3 Health

Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy

STATEMENT OF NEED Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to dose reductions or discontinuation of treatment. In one study, among 105 patients receiving paclitaxel for breast cancer, 36.2% needed dose reductions due to CIPN (Timmins et al, 2021). Whereas in some patients the symptoms improve with time, in others, there is progression with permanent nerve damage (Zajączkowska et al, 2019). At present, the...
i3 Health

Raising the Bar for Patient Outcomes With Immunotherapy in Early-Stage Resectable NSCLC

Target Audience The target audience for this educational initiative is oncologists, oncology NPs, PAs, and nurses, pulmonologists, pulmonology NPs and PAs, pathologists, and pharmacists. Program Overview Are you up to date on the role of immunotherapy in the setting of non-small cell lung cancer (NSCLC)? In this educational activity, experts Heather Wakelee, MD, and Meghan Ramsey, MD, explore how to select patients with early-stage resectable NSCLC who may derive benefit from immunotherap...
Postgraduate Institute for Medicine and Spire Learning.

Recent Advances in the Management of Patients with Advanced Hepatocellular Carcinoma: How Does Your Approach Compare with the Experts’?

Target Audience This activity is intended for US-based hematologists/oncologists, hepatologists, gastroenterologists, interventional radiologists, pathologists, and other members of the multidisciplinary oncology team (NPs, PAs, pharmacists) responsible for the care of patients with HCC. Program Overview This case-based enduring virtual activity is designed to improve clinicians’ ability to use an evidence-based approach for the selection of therapies for the treatment of patients with ...
Med Learning Group.

Applying the Latest Clinical Data in Multiple Myeloma Patient Care in the Community Setting

In recent years, there have been significant advances in multiple myeloma (MM) management, including approvals of new drugs and treatment combinations. For some patients, however, the benefits of these advances remain elusive: disparities in MM care among Black patients, who are more likely to be treated in the community setting, persist across the spectrum of MM care. Though evidence-based MM treatment guidelines and consensus statements are available, ongoing studies continue to provide i...
Penn State College of Medicine

Improving Outcomes for Adolescent/Young Adult and Adult Patients with ALL: Evaluating the Impact of Immunotherapy

Target Audience The activity is intended primarily for hematology/oncology and medical oncology physicians and advanced practitioners caring for adult and AYA patients. Pediatric hematology/oncology and oncology clinicians who care for AYA patients may also find this material useful. Program Overview On-demand Oncology Expert Exchange: Clinical Case Challenge activity (Virtual Video Roundtable with Clinical Cases) with compelling reinforcing features. This initiative aims to close knowled...
Catalyst Medical Education, LLC and AKH Inc., Advancing Knowledge in Healthcare

Evolving Treatment Paradigms in HR-Positive, HER2-Negative Breast Cancer: Integrating the Latest Evidence Into Clinical Practice

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview Advances in therapy for patients with hormone receptor"positive (HR+)/human epidermal growth factor receptor 2"negative (HER2-) breast cancer have the potential to reduce disease recurrence and risk of mortality. However, the complex and evolving treatment landscap...
Postgraduate Institute for Medicine and RME Collaborative

Overcoming Barriers to Equitable Care in Hepatocellular Carcinoma: Integrating New Evidence Into Clinical Practice

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview In rural and underserved communities, the incidence of hepatocellular carcinoma (HCC) continues to rise steadily, especially among Blacks and non-Hispanic Whites. Unique challenges in these areas such as oncology workforce shortages and transportation barriers exacerbate the...
Postgraduate Institute for Medicine and RME Collaborative

Mitigating Disparities in Prostate Cancer Care: Strategies to Promote Equitable Care Across the Continuum

TARGET AUDIENCE This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. PROGRAM OVERVIEW Prostate cancer is among the most common cancers in the United States. In rural and underserved areas of the country, patients with prostate cancer often have poor outcomes due to limited access to care, lack of subspecialists, and long travel distances to treatment centers. I...
Postgraduate Institute for Medicine and RME Collaborative

Integrating the Latest Evidence on Immune Checkpoint Inhibitors Into the Management of Advanced Non-Small Cell Lung Cancer

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview Rural counties in the US face a higher incidence of lung cancer than urban areas and also have higher rates of cancer-related mortality and other negative treatment outcomes. These statistics underscore the need for increased education among oncology clinicians in order to i...
Relias LLC

Integrating the Latest Evidence on Immune Checkpoint Inhibitors Into the Management of Advanced Non-Small Cell Lung Cancer

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview Rural counties in the US face a higher incidence of lung cancer than urban areas and also have higher rates of cancer-related mortality and other negative treatment outcomes. These statistics underscore the need for increased education among oncology clinicians in order to i...
Postgraduate Institute for Medicine and RME Collaborative.

Management of Urothelial Carcinoma: Strategies for Addressing Health Disparities and Promoting Equitable Care

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview The treatment landscape has evolved significantly for patients with advanced/metastatic urothelial carcinoma. With new evidence and indications for immunotherapy and other targeted therapies, oncology clinicians are challenged to stay abreast of updated practice guidelines, ...
Postgraduate Institute for Medicine and RME Collaborative.

Updates in the Diagnosis and Management of Chronic Lymphocytic Leukemia: Strategies for Addressing Disparities in Patient Care and Outcomes

Target Audience This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. Program Overview Advances in chronic lymphocytic leukemia (CLL) testing and therapy have redefined the standard of care in recent years, prompting updates to current guideline recommendations. At the same time, findings from ongoing clinical trials continue to inform treatment options and de...
Postgraduate Institute for Medicine and RME Collaborative.

Refining Management of Classical Hodgkin Lymphoma: What’s on the Horizon for Pediatric Management and AYA Survivorship

Target Audience The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, hematologic oncologists, medical oncologists, hematopathologists, primary care providers, family practitioner internists, hematology/oncology nurses and nurse navigators, nurse practitioners, physician assistants, and pharmacists. Program Overview New treatments are poised to expand the armamentarium for pediatric classical Hodgkin lymphoma (cHL). Given the...
Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders, Inc (NORD)

Transfusion-Related Iron Overload"Evidence-Based Approaches to Improve Chelation Outcomes

Target Audience This educational activity is directed toward hematologists. Pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with iron overload are also invited to attend. Program Overview Patients who require ongoing red blood cell transfusions, such as individuals with transfusion-dependent thalassemia or sickle cell disease, may develop iron overload. Severe or long-term iron overload can result in a higher ri...
Physicians’ Education Resource®, LLC.

Nursing Management of Cancer Treatment-Induced Cardiotoxicity

Studies have shown that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often result in death. This activity reviews recent advances in the management of cancer teatment-induced cardiotoxicity. STATEMENT OF NEED Several studies reveal that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often result in death. Adverse cardiac effects may occur immediately after cessation of therapy or, in som...
i3 Health

Evolving Paradigms in the Use of Checkpoint Inhibitors for the Management of Patients With Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases with most patients having advanced disease at the time of diagnosis. Recent updates to guidelines have further defined recommendations for screening, diagnosis, and biomarker testing for the early management of NSCLC. However, the COVID-19 pandemic has complicated the diagnosis and management of NSCLC, potentially impacting clinical outcomes in these patients. Treatment paradigms also continue to rapidly...
NJH

Metastatic Colorectal Cancer: Targeting Key Clinical Issues for Oncology Nurses

Target Audience This activity is designed to meet the educational needs of oncology nurses, nurse practitioners and nurse navigators engaged in the care of patients with metastatic colorectal cancer. Program Overview New targeted therapies for metastatic colorectal cancer have increased the need for awareness, education, and training for oncology nursing professionals to better prepare them to confidently manage and educate patients. Learning Objectives Upon completion of this activit...
American Academy of CME, Inc

Metastatic Colorectal Cancer: Targeting Key Clinical Issues for Oncology Nurses

New targeted therapies for metastatic colorectal cancer have increased the need for awareness, education, and training for oncology nursing professionals to better prepare them to confidently manage and educate patients. Upon completion of this activity, participants should be better able to: Assess appropriate treatment options for a patient with mCRC who has failed first- and second-line treatment regimens Outline toxicities and management considerations with specific treatment regi...
American Academy of CME

Putting the CAR(T) Before the Horse: Practicalities of T Cell-Activating Therapies in Multiple Myeloma

ACTIVITY DESCRIPTION Patients with multiple myeloma that is refractory to multiple classes of therapeutics can be particularly difficult to treat. Fortunately, the treatment landscape is expanding, and a range of new therapies for patients with multiply relapsed or refractory multiple myeloma (RRMM) is rapidly emerging. In particular, chimeric antigen receptor (CAR) T-cell therapy is a powerful new immunotherapy that has revolutionized cancer treatment and has been approved for patients with ...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

On the Horizon: HER3-Targeted Antibody-Drug Conjugates for Advanced Solid Tumors An Infographic-Enhanced Journal Club Activity Rationale and Mechanism of Action of HER3-Targeted ADCs for Advanced NSCL

Target Audience This activity has been designed for oncology clinicians and others who may also have an interest in this topic, specifically those focused on lung and/or breast cancer. Program Overview Although treatments for advanced non-small cell lung cancer (NSCLC) and breast cancer are rapidly advancing, these diseases remain incurable. Antibody-drug conjugates (ADCs) offer a novel approach to targeting HER3 as a method of delivering a cytotoxic payload that eliminates tumor cells. T...
Paradigm Medical Communications, LLC

Community Practice Connections™: Transforming How We Treat Sickle Cell Disease: Holistic Approaches to Addressing Clinical Challenges Across the Patient’s Lifespan

Target Audience This activity is directed toward hematologists, pediatricians, emergency medicine clinicians, pain management specialists, specialty NPs, PAs, RNs, and other HCPs involved in the management of patients with SCD. Program Overview Significant progress has been made in the management of sickle cell disease (SCD) in recent years, leading to increased life expectancy for patients. The number of available medications continues to grow; further, novel agents and gene therapies on...
Physicians’ Education Resource®, LLC.

Identifying Patients at High Risk of COVID-19 Complications: Considerations for Community Care to Reduce Morbidity, Mortality, and Hospitalization Risk

Target Audience This activity is designed to meet the educational needs of primary care physicians, internists, pharmacists, nurses, nurse practitioners, physician assistants, and other members of the multidisciplinary team to ensure optimal patient outcomes in outpatient management of COVID-19 infection and potential complications of disease in at-risk populations. Program Overview This program uses a game-based approach to explore the current understanding of COVID risk assessment, diag...
Med Learning Group

A New Path Forward: The Therapeutic Potential of Next Generation BTK Inhibitors in CLL/SLL

Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment plans. Are you ready to incorporate these emerging therapies into your treatment plans? Dr. Sameer Parikh discusses these emerging BTK inhibitors for CLL/SLL, how they differ from current approaches, and future opportunities to introduce these therapies into your clinical decisions. Hear a patient case and the question and answer portion f...
The University of Texas MD Anderson Cancer Center

Early Detection of Women’s Cancers: A Prominent Role for Primary Care and OB/GYNs

Target Audience The educational design of this activity addresses the needs of primary care physicians (PCPs), OB/GYNs, and NPs/PAs working in primary care or women’s care centers involved in the treatment of patients at higher risk for women’s cancers. Program Overview Multi‐cancer early detection panels (MCEDs) have the potential to improve cancer outcomes by enhancing timely screening and detection of multiple cancers at once, including high‐incidence cancers without current gu...
Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC in collaboration with the American College of Osteopathic Obstetricians and Gynecologists (ACOOG).

Ace the Case: Multiple Myeloma Presentation in the Community Setting

Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners. This educational program is designed to meet the educational needs of the members of the care team (oncologists, h...
American Academy of CME

Ace the Case: Treating First Multiple Myeloma Relapse in the Community Setting

Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners. This educational program is designed to meet the educational needs of the members of the care team (oncologists, h...
American Academy of CME

Ace the Case: R/R MM After 4 Lines of Therapy: What are the options?

Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners. This educational program is designed to meet the educational needs of the members of the care team (oncologists, h...
American Academy of CME

Expert Insight into Emerging Treatments for EGFR TKI-Resistant NSCLC and HER2-Positive NSCLC

Target Audience Medical oncologists, thoracic oncologists, pathologists, oncology nurse practitioners, oncology physician assistants, and other HCPs managing patients with NSCLC Program Overview Despite substantial advances in the management of non-small cell lung cancer (NSCLC) during the past decade, advanced NSCLC continues to have persistently low 5-year survival rates and imposes a significant burden on patients. Improved molecular-testing practices and integration of new data on tar...
Relias LLC

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map